

Resource Summary Report

Generated by [RRID](#) on Aug 29, 2026

T3M-4

RRID:CVCL_4056

Type: Cell Line

Proper Citation

RRID:CVCL_4056

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4056

Proper Citation: RRID:CVCL_4056

Description: Cell line T3M-4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: [PMID:6821838](#), [PMID:8426738](#), [PMID:11169959](#), [PMID:11787853](#), [PMID:12692724](#), [PMID:18298655](#), [PMID:22460905](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Japanese., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: T3M-4

Synonyms: T3M4, Panc89, Panc-89, PANC-89, Panc 89

Cross References: BTO:BTO_0002864, CLO:CLO_0050113, EFO:EFO_0002714, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:452, BioSample:SAMN03472207, BioSample:SAMN10988105, cancercellines:CVCL_4056, CCRID:1101HUM-PUMC000815, Cell_Model_Passport:SIDM01469, Cosmic:710873, Cosmic:724641, Cosmic:736281, Cosmic:922257, Cosmic:922263, Cosmic:933528, Cosmic:2546061, Cosmic:2546062, DepMap:ACH-000085, GEO:GSM887684, GEO:GSM888776, GEO:GSM1374814, GEO:GSM1374815, GEO:GSM1374816, IARC_TP53:1561, IARC_TP53:16746, LiGeA:CCLE_195, PharmacDB:T3M4_1557_2019, Progenetix:CVCL_4056, RCB:RCB1021,

Wikidata:Q54971538

ID: CVCL_4056

Record Creation Time: 20220427T221618+0000

Record Last Update: 20260815T235934+0000

Ratings and Alerts

No rating or validation information has been found for T3M-4.

No alerts have been found for T3M-4.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Klink N, et al. (2026) Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors. Nature communications, 17(1).

Zhang S, et al. (2026) Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. Cell reports. Medicine, 7(3), 102660.

Tang J, et al. (2025) CD44 identified as a diagnostic biomarker for highly malignant CA19-9 negative pancreatic cancer. Cancer letters, 622, 217713.

Zhu Y, et al. (2025) Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer. Frontiers in immunology, 16, 1524899.

Lum MA, et al. (2025) Small-molecule modulators of B56-PP2A restore 4E-BP function to suppress eIF4E-dependent translation in cancer cells. The Journal of clinical investigation, 135(4).

Wang S, et al. (2025) IFN- γ -driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. Nature communications, 16(1), 10733.

Dardare J, et al. (2024) DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib. Cell death discovery, 10(1), 411.

He C, et al. (2024) Vitamin B6 Competition in the Tumor Microenvironment Hampers Antitumor Functions of NK Cells. Cancer discovery, 14(1), 176.

Haastrup MO, et al. (2024) Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function. *Molecular cancer research : MCR*, 22(2), 197.

Francis JW, et al. (2024) FAM86A methylation of eEF2 links mRNA translation elongation to tumorigenesis. *Molecular cell*.

Shrestha H, et al. (2024) The Janus kinase 1 is critical for pancreatic cancer initiation and progression. *Cell reports*, 43(5), 114202.

Shah A, et al. (2023) Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies. *NPJ precision oncology*, 7(1), 74.

Yoon SJ, et al. (2023) Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. *Cancer research*, 83(9), 1426.

Aasted MKM, et al. (2023) Targeting Solid Cancers with a Cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly O-glycosylated Proteins. *Molecular cancer therapeutics*, 22(10), 1204.

Witz A, et al. (2023) CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines. *Scientific reports*, 13(1), 18741.

Marimuthu S, et al. (2022) MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. *Molecular cancer research : MCR*, 20(8), 1208.

Dardare J, et al. (2022) DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy. *Frontiers in oncology*, 12, 1052163.

Ruivo CF, et al. (2022) Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression. *Gut*, 71(10), 2043.

Dorsch M, et al. (2021) Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. *Cell reports*, 37(8), 110056.

Somerville TD, et al. (2020) Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. *eLife*, 9.